semaglutide and beta blockers Weight loss drug reduces risk of adverse cardiovascular events by 20% among overweight, obese patients Chest pain and heart skipped

Saxenda, the second to be approved, only achieved middling weight-management results for a large share of those who took it, and physicians were reticent to prescribe weight-loss medications after the disastrous effects of drugs such as fen-phen were revealed in the late 90s

Tyna Moore: [00:02:57] Thank you

In 2 murine models of atherosclerosis (ApoE / and LDLr / ), liraglutide and semaglutide showed significant reductions of aortic plaque areas, at least partially independent of changes in body weight

The limits of the study Among the studys limitations: It was conducted within the VA health system, which serves a population that is mostly older, white and male, although Al-Aly said the results were consistent in more than 35,000 women